EA201071111A1 - HALF-DISPOSED 6-HETEROYARYLIMIDAZO [1,2-a] PYRIDINES DERIVATIVES, THEIR RECEIVING AND THEIR APPLICATION IN THERAPY - Google Patents
HALF-DISPOSED 6-HETEROYARYLIMIDAZO [1,2-a] PYRIDINES DERIVATIVES, THEIR RECEIVING AND THEIR APPLICATION IN THERAPYInfo
- Publication number
- EA201071111A1 EA201071111A1 EA201071111A EA201071111A EA201071111A1 EA 201071111 A1 EA201071111 A1 EA 201071111A1 EA 201071111 A EA201071111 A EA 201071111A EA 201071111 A EA201071111 A EA 201071111A EA 201071111 A1 EA201071111 A1 EA 201071111A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- alkyl
- group
- optionally substituted
- halogen
- therapy
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 150000003222 pyridines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 229910003827 NRaRb Inorganic materials 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Соединение формулы (I), где Rозначает фенильную или нафтильную группу, гетероарильную группу или гетероциклическую группу, необязательно замещенную одним или несколькими атомами или группами; Het означает моноциклическую гетероарильную группу, содержащую от 5 до 6 атомов, включая 1-3 гетероатома, выбранных из N, О и S; Х означает от 1 до 3 заместителей, одинаковых или отличающихся друг от друга, выбранных из водорода, галогена, (C-С)алкила, (C-С)алкокси, NRaRb, нитро, циано, причем (C-С)алкил необязательно может быть замещен одной или несколькими группами, выбранными из галогена, (C-С)алкокси, (C-С)галогеналкокси, NRaRb или гидроксила; R в положении 3, 5, 7 или 8 имидазо[1,2-а]пиридина означает от 1 до 4 заместителей, одинаковых или отличающихся друг от друга, выбранных из водорода, галогена, (C-С)алкила, галоген(C-С)алкила, (C-С) алкокси; Rи Rнезависимо друг от друга означают атом водорода, (C-C)алкильную группу, необязательно замещенную группой Rf, или арильную группу, необязательно замещенную; Rозначает атом водорода, (C-С)алкильную группу, необязательно замещенную группой Rf; арильную группу, необязательно замещенную, в виде основания или кислотно-аддитивной соли. Применение в терапии и способ синтеза.A compound of formula (I) wherein R 2 is a phenyl or naphthyl group, a heteroaryl group, or a heterocyclic group optionally substituted with one or more atoms or groups; Het means a monocyclic heteroaryl group containing from 5 to 6 atoms, including 1-3 heteroatoms selected from N, O and S; X means from 1 to 3 substituents identical or different from each other, selected from hydrogen, halogen, (C-C) alkyl, (C-C) alkoxy, NRaRb, nitro, cyano, and (C-C) alkyl may optionally be substituted by one or more groups selected from halogen, (C-C) alkoxy, (C-C) haloalkoxy, NRaRb or hydroxyl; R in position 3, 5, 7 or 8 of imidazo [1,2-a] pyridine means from 1 to 4 substituents identical or different from each other, selected from hydrogen, halogen, (C-C) alkyl, halogen (C- C) alkyl, (C-C) alkoxy; R <4> and R <10> independently of each other means a hydrogen atom, a (C-C) alkyl group, optionally substituted by Rf, or an aryl group, optionally substituted; R3 represents a hydrogen atom, a (C-C) alkyl group optionally substituted by a Rf group; an aryl group, optionally substituted, in the form of a base or an acid addition salt. Use in therapy and method of synthesis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0801585A FR2928924B1 (en) | 2008-03-21 | 2008-03-21 | POLYSUBSTITUTED DERIVATIVES OF 6-HETEROARYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| PCT/FR2009/000298 WO2009144392A1 (en) | 2008-03-21 | 2009-03-20 | Polysubstituted derivatives of 6-heteroaryl-imidazo[l,2- α] pyridines, and preparation and therapeutic use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201071111A1 true EA201071111A1 (en) | 2011-08-30 |
Family
ID=39764971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201071111A EA201071111A1 (en) | 2008-03-21 | 2009-03-20 | HALF-DISPOSED 6-HETEROYARYLIMIDAZO [1,2-a] PYRIDINES DERIVATIVES, THEIR RECEIVING AND THEIR APPLICATION IN THERAPY |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8088765B2 (en) |
| EP (1) | EP2262804B1 (en) |
| JP (1) | JP5508384B2 (en) |
| KR (1) | KR20100124830A (en) |
| CN (2) | CN103145747B (en) |
| AR (1) | AR070995A1 (en) |
| AU (1) | AU2009253232B2 (en) |
| BR (1) | BRPI0910309A2 (en) |
| CA (1) | CA2719118C (en) |
| CL (1) | CL2009000699A1 (en) |
| CO (1) | CO6300864A2 (en) |
| EA (1) | EA201071111A1 (en) |
| FR (1) | FR2928924B1 (en) |
| IL (1) | IL208247A0 (en) |
| MA (1) | MA32248B1 (en) |
| ME (1) | ME01112B (en) |
| MX (1) | MX2010010268A (en) |
| NZ (1) | NZ588083A (en) |
| PE (1) | PE20091694A1 (en) |
| TW (1) | TW200942541A (en) |
| UY (1) | UY31730A (en) |
| WO (1) | WO2009144392A1 (en) |
| ZA (1) | ZA201006725B (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2928923B1 (en) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS |
| FR2928922B1 (en) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | DERIVATIVES OF POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| JP5658664B2 (en) | 2008-06-25 | 2015-01-28 | フォルム ファーマシューティカルズ、インコーポレイテッド | 1,2-disubstituted heterocyclic compounds |
| TWI453207B (en) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith |
| RS52838B (en) | 2009-05-07 | 2013-10-31 | Envivo Pharmaceuticals Inc. | Phenoxymethyl heterocyclic compounds |
| FR2953520B1 (en) * | 2009-12-04 | 2011-11-25 | Sanofi Aventis | DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| TWI429628B (en) * | 2010-03-29 | 2014-03-11 | Univ Taipei Medical | Indolyl or indolinyl hydroxamate compounds |
| LT2624696T (en) | 2010-10-06 | 2017-03-10 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
| US8975276B2 (en) | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| CN103214481B (en) * | 2012-01-21 | 2016-08-03 | 中国科学院上海药物研究所 | Novel imidazole also [1,2-a] pyridine compounds and their, its preparation method, comprise the medical composition and its use of this compounds |
| ES2928164T3 (en) | 2015-10-19 | 2022-11-15 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| TWI763641B (en) | 2015-11-19 | 2022-05-11 | 美商英塞特公司 | Heterocyclic compounds as immunomodulators |
| KR20180100585A (en) | 2015-12-22 | 2018-09-11 | 인사이트 코포레이션 | Heterocyclic compounds as immunomodulators |
| MA44860A (en) | 2016-05-06 | 2019-03-13 | Incyte Holdings Corp | HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3472167T2 (en) | 2016-06-20 | 2023-02-28 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CN106631970A (en) * | 2016-12-14 | 2017-05-10 | 贵州大学 | Preparation method of 6-benzoyl-1H-indole |
| MY197635A (en) | 2016-12-22 | 2023-06-29 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
| CR20190317A (en) | 2016-12-22 | 2019-09-13 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| ES2874756T3 (en) | 2016-12-22 | 2021-11-05 | Incyte Corp | Triazolo [1,5-A] pyridine derivatives as immunomodulators |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| HUE061258T2 (en) | 2018-03-30 | 2023-05-28 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| CR20200614A (en) | 2018-05-11 | 2021-04-27 | Incyte Corp | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
| AR119624A1 (en) | 2019-08-09 | 2021-12-29 | Incyte Corp | SALTS OF A PD-1/PD-L1 INHIBITOR |
| CR20220190A (en) | 2019-09-30 | 2022-06-15 | Incyte Corp | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| KR20220101664A (en) | 2019-11-11 | 2022-07-19 | 인사이트 코포레이션 | Salts and crystalline forms of PD-1/PD-L1 inhibitors |
| EP4138792A4 (en) * | 2020-04-24 | 2024-04-24 | The Regents of the University of California | Nurr1 receptor modulators and uses thereof |
| TW202233615A (en) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Crystalline form of a pd-1/pd-l1 inhibitor |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
| EP4370518A1 (en) | 2021-07-16 | 2024-05-22 | Sanofi | Imidazo[1,2-b][1,2,4]triazol derivatives for use in therapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20084341B (en) | 2003-02-26 | 2008-03-25 | Sugen Inc | Aminoheteroaryl compounds as protein kinase inhibitors |
| FR2903107B1 (en) * | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | IMIDAZOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| FR2903105A1 (en) * | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | 2-BENZOYL-IMIDAZOPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| FR2906250B1 (en) * | 2006-09-22 | 2008-10-31 | Sanofi Aventis Sa | DERIVATIVES OF 2-ARYL-6PHENYL-IMIDAZO (1,2-A) PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| WO2008104077A1 (en) * | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
| FR2928923B1 (en) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS |
| FR2928922B1 (en) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | DERIVATIVES OF POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
| FR2928921B1 (en) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO-1,2-A! PYRIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
-
2008
- 2008-03-21 FR FR0801585A patent/FR2928924B1/en active Active
-
2009
- 2009-03-19 PE PE2009000414A patent/PE20091694A1/en not_active Application Discontinuation
- 2009-03-19 AR ARP090100988A patent/AR070995A1/en not_active Application Discontinuation
- 2009-03-20 EA EA201071111A patent/EA201071111A1/en unknown
- 2009-03-20 MX MX2010010268A patent/MX2010010268A/en active IP Right Grant
- 2009-03-20 CL CL2009000699A patent/CL2009000699A1/en unknown
- 2009-03-20 TW TW098109256A patent/TW200942541A/en unknown
- 2009-03-20 KR KR1020107023402A patent/KR20100124830A/en not_active Application Discontinuation
- 2009-03-20 UY UY0001031730A patent/UY31730A/en not_active Application Discontinuation
- 2009-03-20 JP JP2011500259A patent/JP5508384B2/en not_active Expired - Fee Related
- 2009-03-20 AU AU2009253232A patent/AU2009253232B2/en not_active Ceased
- 2009-03-20 CN CN201310049249.7A patent/CN103145747B/en not_active Expired - Fee Related
- 2009-03-20 NZ NZ588083A patent/NZ588083A/en not_active IP Right Cessation
- 2009-03-20 WO PCT/FR2009/000298 patent/WO2009144392A1/en active Application Filing
- 2009-03-20 CN CN200980118584.XA patent/CN102036989B/en not_active Expired - Fee Related
- 2009-03-20 BR BRPI0910309A patent/BRPI0910309A2/en active Search and Examination
- 2009-03-20 ME MEP-2010-150A patent/ME01112B/en unknown
- 2009-03-20 CA CA2719118A patent/CA2719118C/en not_active Expired - Fee Related
- 2009-03-20 EP EP09754042.1A patent/EP2262804B1/en active Active
-
2010
- 2010-09-14 US US12/881,820 patent/US8088765B2/en not_active Expired - Fee Related
- 2010-09-19 IL IL208247A patent/IL208247A0/en unknown
- 2010-09-20 CO CO10115913A patent/CO6300864A2/en not_active Application Discontinuation
- 2010-09-20 ZA ZA2010/06725A patent/ZA201006725B/en unknown
- 2010-10-19 MA MA33274A patent/MA32248B1/en unknown
-
2011
- 2011-11-08 US US13/291,660 patent/US8598166B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| UY31730A (en) | 2009-11-10 |
| CN103145747A (en) | 2013-06-12 |
| US8088765B2 (en) | 2012-01-03 |
| BRPI0910309A2 (en) | 2015-09-29 |
| US20110065700A1 (en) | 2011-03-17 |
| CN103145747B (en) | 2015-06-17 |
| ZA201006725B (en) | 2011-11-30 |
| MX2010010268A (en) | 2011-04-05 |
| ME01112B (en) | 2012-12-20 |
| CN102036989A (en) | 2011-04-27 |
| JP2011515381A (en) | 2011-05-19 |
| NZ588083A (en) | 2012-07-27 |
| CO6300864A2 (en) | 2011-07-21 |
| KR20100124830A (en) | 2010-11-29 |
| FR2928924A1 (en) | 2009-09-25 |
| AU2009253232A1 (en) | 2009-12-03 |
| EP2262804B1 (en) | 2014-12-03 |
| PE20091694A1 (en) | 2009-11-20 |
| AR070995A1 (en) | 2010-05-19 |
| TW200942541A (en) | 2009-10-16 |
| CL2009000699A1 (en) | 2010-04-09 |
| IL208247A0 (en) | 2010-12-30 |
| EP2262804A1 (en) | 2010-12-22 |
| US8598166B2 (en) | 2013-12-03 |
| WO2009144392A1 (en) | 2009-12-03 |
| CN102036989B (en) | 2014-05-07 |
| US20120053202A1 (en) | 2012-03-01 |
| CA2719118C (en) | 2016-07-26 |
| FR2928924B1 (en) | 2010-04-23 |
| JP5508384B2 (en) | 2014-05-28 |
| MA32248B1 (en) | 2011-04-01 |
| AU2009253232B2 (en) | 2013-07-11 |
| CA2719118A1 (en) | 2009-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201071111A1 (en) | HALF-DISPOSED 6-HETEROYARYLIMIDAZO [1,2-a] PYRIDINES DERIVATIVES, THEIR RECEIVING AND THEIR APPLICATION IN THERAPY | |
| EA201071113A1 (en) | HALF-DIVIDED DERIVATIVES 2-HETEROARYL-6-PHENYLIMIDAZO [1,2-α] Pyridine, THEIR RECEIVING AND THEIR APPLICATION IN THERAPY | |
| RU2018131134A (en) | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | |
| EA201071112A1 (en) | Derivatives of polysubstituted 2-aryl-6-phenylimidazo [1,2-a] pyridine, the method for producing them and their use in therapy | |
| EA201071110A1 (en) | HALF-DIVIDED DERIVATIVES 2-ARYL-6-PHENYLIMIDAZO [1,2-a] Pyridine, THEIR RECEIVING AND THEIR APPLICATION IN THERAPY | |
| EA201170099A1 (en) | SUBSTITUTED PYRIMIDIN-4-ONE DERIVATIVES | |
| NO20051051L (en) | Derivatives of dioxane-2-alkylcarbamates, processes for their preparation and use of the same in therapeutic agents | |
| MY145603A (en) | 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | |
| RU2009132186A (en) | METHOD FOR PRODUCING 2-AMINOTIAZOLE COMPOUNDS AS KINASE INHIBITORS | |
| EA201171000A1 (en) | Derivative azaspranililkilkarbamatov in the form of 5-member heterocycles, the method of their production and use in therapy | |
| CY1112997T1 (en) | NEW IMIDAZO [1,5-a] Pyridine Derivatives, Their Preparation Process and the Pharmaceutical Compositions Containing It | |
| MX2013002558A (en) | Hetero ring-fused imidazole derivative having ampk activating effect. | |
| MX2009004920A (en) | Novel aminopyrimidine derivatives as plk1 inhibitors. | |
| WO2011141716A3 (en) | Modulators of chk-1 activity | |
| EA201101566A1 (en) | IMIDAZOL DERIVATIVES AND THEIR APPLICATION AS CYLIN-dependent KINAZ MODULATORS | |
| EA201171385A1 (en) | CYCLOPENT DERIVATIVES [C] Pyrrolylalkylcarbamates of 5-member heterocycles, method of their production and their use in therapy | |
| WO2010010288A3 (en) | Alkyl thiazole carbamate derivatives, preparation thereof, and use thereof as faah enzyme inhibitors | |
| EA201170093A1 (en) | SUBSTITUTED N-OXYDPYRAZINE DERIVATIVES | |
| EA201070817A1 (en) | IMIDAZO [1,2-α] PYRIDIN-2-CARBOXAMID DERIVATIVES, THEIR RECEIVING AND THEIR USE IN THERAPY | |
| AR116022A1 (en) | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | |
| WO2005095399A3 (en) | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | |
| NZ593344A (en) | Derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics | |
| TW200942538A (en) | 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof | |
| WO2009106752A3 (en) | Derivatives of 2-heteroaroyl-imidazol[1,2-a]pyridine, preparation thereof and therapeutic application thereof | |
| EA200802427A1 (en) | NEW COMPOUNDS 1H-INDOL-1-IL-UREA, METHOD FOR THEIR RECEPTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING |